Great Trees Require Strong Roots: Evaluating Data and Delegation Doctrine Underlying Proposed Reforms to FDA's...

Area of Science:

• Health Policy
• Regulatory Science
• Pharmaceutical Policy

Background:

• The US Food and Drug Administration (FDA) faces scrutiny over drug approval processes.
• The accelerated approval pathway allows earlier drug access but necessitates post-market confirmatory trials.
• Concerns exist regarding potential agency capture and political influence on regulatory decisions.

Purpose of the Study:

• To analyze the factors contributing to delays in confirmatory trials for accelerated approval drugs.
• To examine the role of agency capture and politicized discretion within the FDA.
• To propose solutions for improving the efficiency and integrity of the accelerated approval process.

Main Methods:

• Qualitative analysis of the "Missing the Forest for the Trees: Aduhelm, Accelerated Approvals & the Agency" paper.
• Review of a three-drug case study.
• Incorporation of insights from interviews with twenty-three unnamed FDA officials.

Main Results:

• Agency capture and politicized discretion are identified as key drivers of delays in confirmatory trials.
• The study highlights broader concerns regarding the FDA's internal workings and decision-making processes.
• Two innovative policy solutions are proposed to address these issues.

Conclusions:

• Dr. Herder's analysis provides nuanced insight into FDA operations and the challenges of the accelerated approval pathway.
• The proposed solutions require further corroborative evidence and careful consideration of institutional and constitutional constraints.
• Balancing agency expertise, data-driven decisions, and delegation remains a critical challenge in pharmaceutical regulation.